FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W628361250> ?p ?o ?g. }

• W628361250 endingPage "1598" @default.
• W628361250 startingPage "1597" @default.
• W628361250 abstract "Dear Editor, In the current clinical practice, minimal criteria to define thrombotic thrombocytopenic purpura (TTP) are the presence of signs of microangiopathic haemolytic anaemia and low platelet (PLT) count [1]. TTP relapses (20–50 % of cases) are defined as the recurrence of acute TTP symptoms 30 days after the first episode, while exacerbations occur within 30 days [2]. We here report on an atypical case of acquired TTP where minimal criteria were met only after many recurrent macrovascular ischemic events. A 42-year old Caucasian woman with a history of coronary and cerebral ischemic events was admitted on June 2013, following a recurrent transient ischemic attack (TIA). She had severe anaemia and thrombocytopenia with laboratory signs of intravascular haemolysis and mild renal impairment. In her past medical history, recurrent ischemic events occurred from 2008 to 2012, without known risk factors and regardless of treatment. The patient was treated with acetyl salicylic acid (100 mg daily) after the first ischemic event (stroke, in 2008) plus anticoagulation with warfarin after the third stroke (in 2010), with a good compliance . Screening for autoimmune disease, Factor V Leiden and Factor II (G20210A) gene mutations and circulating anticoagulants were normal. Blood cell count and peripheral blood smear did not show any significant abnormalities in the past, without evidence of schistocytes; a slight decrease in PLT count (92×109/L) was observed only once (in 2012), at that time, ADAMTS13 activity (ADAMTS-13: AC) was 65 %. At the current admission, ADAMTS-13: AC was 6 %, inhibitors were at high titer (2 Bethesda Units, BU). A genetic test for Upshaw-Schulman syndrome was normal. Therapeutic plasma exchange (TPE) and prednisone (1 mg/kg body weight) treatment was started and maintained until clinical and haematological remission [3]. TPE (Gambro®, Italy) was performed daily for 3 weeks with an increase of ADAMTS13: AC to 50 %. TTP exacerbated after 10 days, it was well controlled with weekly rituximab (375 mg/m body surface), for 4 weeks. A relapse occurred after 37 days with the patient presenting seizures: ADAMTS-13: AC, which was 54 % after the last treatment, had decreased to 6 %. A second course of weekly rituximab, followed by maintenance with azathioprine (50 mg twice daily for 10 days, then 50 mg, daily) was followed by clinical and haematological remission. Rituximab was re-administered for its previous rapid efficacy and to prevent further complications [4]. The patient is alive and free from recurrences for 18 months; azathioprine maintenance is still on course. ADAMTS13: AC is monitored every 4 months, and it ranges from 45 to 51 %; inhibitors are no longer detectable. * Alessandro Lucchesi alessandro.lucchesi@irst.emr.it" @default.
• W628361250 created "2016-06-24" @default.
• W628361250 creator A5025476428 @default.
• W628361250 creator A5031940866 @default.
• W628361250 creator A5039120727 @default.
• W628361250 creator A5045339988 @default.
• W628361250 creator A5071210944 @default.
• W628361250 creator A5087989451 @default.
• W628361250 creator A5089025495 @default.
• W628361250 date "2015-06-09" @default.
• W628361250 modified "2023-10-13" @default.
• W628361250 title "Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report" @default.
• W628361250 cites W2008269539 @default.
• W628361250 cites W2010802708 @default.
• W628361250 cites W2020179687 @default.
• W628361250 cites W2026994059 @default.
• W628361250 cites W2039241798 @default.
• W628361250 cites W2052449117 @default.
• W628361250 cites W2063755483 @default.
• W628361250 cites W2069730164 @default.
• W628361250 cites W2083670536 @default.
• W628361250 cites W2096694969 @default.
• W628361250 doi "https://doi.org/10.1007/s00277-015-2415-y" @default.
• W628361250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26051903" @default.
• W628361250 hasPublicationYear "2015" @default.
• W628361250 type Work @default.
• W628361250 sameAs 628361250 @default.
• W628361250 citedByCount "1" @default.
• W628361250 countsByYear W6283612502020 @default.
• W628361250 crossrefType "journal-article" @default.
• W628361250 hasAuthorship W628361250A5025476428 @default.
• W628361250 hasAuthorship W628361250A5031940866 @default.
• W628361250 hasAuthorship W628361250A5039120727 @default.
• W628361250 hasAuthorship W628361250A5045339988 @default.
• W628361250 hasAuthorship W628361250A5071210944 @default.
• W628361250 hasAuthorship W628361250A5087989451 @default.
• W628361250 hasAuthorship W628361250A5089025495 @default.
• W628361250 hasBestOaLocation W6283612502 @default.
• W628361250 hasConcept C126322002 @default.
• W628361250 hasConcept C127413603 @default.
• W628361250 hasConcept C16005928 @default.
• W628361250 hasConcept C164705383 @default.
• W628361250 hasConcept C187212893 @default.
• W628361250 hasConcept C194409129 @default.
• W628361250 hasConcept C2778585876 @default.
• W628361250 hasConcept C2780645631 @default.
• W628361250 hasConcept C2780868729 @default.
• W628361250 hasConcept C2908767545 @default.
• W628361250 hasConcept C71924100 @default.
• W628361250 hasConcept C78519656 @default.
• W628361250 hasConcept C89560881 @default.
• W628361250 hasConceptScore W628361250C126322002 @default.
• W628361250 hasConceptScore W628361250C127413603 @default.
• W628361250 hasConceptScore W628361250C16005928 @default.
• W628361250 hasConceptScore W628361250C164705383 @default.
• W628361250 hasConceptScore W628361250C187212893 @default.
• W628361250 hasConceptScore W628361250C194409129 @default.
• W628361250 hasConceptScore W628361250C2778585876 @default.
• W628361250 hasConceptScore W628361250C2780645631 @default.
• W628361250 hasConceptScore W628361250C2780868729 @default.
• W628361250 hasConceptScore W628361250C2908767545 @default.
• W628361250 hasConceptScore W628361250C71924100 @default.
• W628361250 hasConceptScore W628361250C78519656 @default.
• W628361250 hasConceptScore W628361250C89560881 @default.
• W628361250 hasIssue "9" @default.
• W628361250 hasLocation W6283612501 @default.
• W628361250 hasLocation W6283612502 @default.
• W628361250 hasLocation W6283612503 @default.
• W628361250 hasOpenAccess W628361250 @default.
• W628361250 hasPrimaryLocation W6283612501 @default.
• W628361250 hasRelatedWork W1971316336 @default.
• W628361250 hasRelatedWork W2003130009 @default.
• W628361250 hasRelatedWork W2026994059 @default.
• W628361250 hasRelatedWork W2047645365 @default.
• W628361250 hasRelatedWork W2111739542 @default.
• W628361250 hasRelatedWork W2390899018 @default.
• W628361250 hasRelatedWork W2527696784 @default.
• W628361250 hasRelatedWork W3032157229 @default.
• W628361250 hasRelatedWork W4249042456 @default.
• W628361250 hasRelatedWork W53249031 @default.
• W628361250 hasVolume "94" @default.
• W628361250 isParatext "false" @default.
• W628361250 isRetracted "false" @default.
• W628361250 magId "628361250" @default.
• W628361250 workType "article" @default.